Drug Profile


Alternative Names: APTA-2217; B 9302-107; BY 217; BYK 20869; Daliresp; Daxas; IN-ALR 01; Libertek

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nycomed
  • Developer Actavis; Mitsubishi Tanabe Pharma Corporation; Nycomed; Takeda; Takeda Pharmaceuticals International GmbH
  • Class Aminopyridines; Antiallergics; Antiasthmatics; Benzamides; Cyclopropanes; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • No development reported Alzheimer's disease; Asthma; Atopic dermatitis; Non-alcoholic steatohepatitis; Plaque psoriasis; Schizophrenia; Type 2 diabetes mellitus

Most Recent Events

  • 22 Jun 2017 UK National Institute for Health and Clinical Excellence approves roflumilast for treatment of Chronic obstructive pulmonary disease in United Kingdom
  • 03 Sep 2016 Adverse events data from a phase-III trial in Chronic obstructive pulmonary disease presented at the 26th Annual Congress of the European Respiratory Society (ERS-2016)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top